| Dr Corrine Leistikow, MD | |
|
1001 Noble St, Fairbanks, AK 99701-4922 | |
| (907) 459-3511 | |
| (907) 459-3588 |
| Full Name | Dr Corrine Leistikow |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 38 Years |
| Location | 1001 Noble St, Fairbanks, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417922774 | NPI | - | NPPES |
| 1007182 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 2487 (Alaska) | Secondary |
| 207Q00000X | Family Medicine | 2487 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairbanks Memorial Hospital | Fairbanks, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tanana Valley Clinic Llc | 5698056901 | 105 |
News Archive
A new study from American Cancer Society researchers finds it's not just how much physical activity you get, but how much time you spend sitting that can affect your risk of death. Researchers say time spent sitting was independently associated with total mortality, regardless of physical activity level. They conclude that public health messages should promote both being physically active and reducing time spent sitting. The study appears early online in the American Journal of Epidemiology.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
Research presented in a six-hour symposium on carotid artery disease at the 29th Annual Scientific Meeting of the Society of Interventional Radiology showed carotid artery stenting to be safe and effective for highrisk patients.
› Verified 2 days ago
| Entity Name | Tanana Valley Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922559558 PECOS PAC ID: 5698056901 Enrollment ID: O20161228001991 |
News Archive
A new study from American Cancer Society researchers finds it's not just how much physical activity you get, but how much time you spend sitting that can affect your risk of death. Researchers say time spent sitting was independently associated with total mortality, regardless of physical activity level. They conclude that public health messages should promote both being physically active and reducing time spent sitting. The study appears early online in the American Journal of Epidemiology.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
Research presented in a six-hour symposium on carotid artery disease at the 29th Annual Scientific Meeting of the Society of Interventional Radiology showed carotid artery stenting to be safe and effective for highrisk patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Corrine Leistikow, MD 1001 Noble St, Fairbanks, AK 99701-4922 Ph: (907) 459-3500 | Dr Corrine Leistikow, MD 1001 Noble St, Fairbanks, AK 99701-4922 Ph: (907) 459-3511 |
News Archive
A new study from American Cancer Society researchers finds it's not just how much physical activity you get, but how much time you spend sitting that can affect your risk of death. Researchers say time spent sitting was independently associated with total mortality, regardless of physical activity level. They conclude that public health messages should promote both being physically active and reducing time spent sitting. The study appears early online in the American Journal of Epidemiology.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Mercy Health System to deploy NextGen® EHR and NextGensm Health Information Exchange.
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
Research presented in a six-hour symposium on carotid artery disease at the 29th Annual Scientific Meeting of the Society of Interventional Radiology showed carotid artery stenting to be safe and effective for highrisk patients.
› Verified 2 days ago
Dr. Mark Andrew Clifford, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 122 1st Ave, Suite 600, Fairbanks, AK 99701 Phone: 907-750-4124 Fax: 808-433-1558 | |
Abigail J Klager, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 W Cowles St, Fairbanks, AK 99701 Phone: 907-451-6682 | |
Angela Lucien, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 W Cowles St, Fairbanks, AK 99701 Phone: 907-452-8251 | |
Dr. Melinda F Evans, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1606 23rd Ave, Fairbanks, AK 99701 Phone: 907-455-4567 Fax: 907-458-1581 | |
Dr. Natalie Seibert Mayer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1867 Airport Way, Suite 120b, Fairbanks, AK 99701 Phone: 907-457-5050 Fax: 907-457-5034 | |
Dr. Peter John Dillon Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Noble St, Fairbanks, AK 99701 Phone: 907-459-3500 Fax: 907-458-2628 | |
Dr. Russell Scott Pierce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 751 Old Richardson Hwy Ste 200, Fairbanks, AK 99701 Phone: 907-457-9420 Fax: 907-457-1098 |